Can Ozempic and GLP-1 Agonists Treat Arthritis? What the Research Shows
- 2 days ago
- 5 min read
By Dr. Jeffrey Peng, MD · Published March 4, 2026 · 8 min read
Watch the Full Video
GLP-1 receptor agonists such as Ozempic (semaglutide), Wegovy, and Mounjaro (tirzepatide) have transformed the landscape of medical weight loss. Originally developed for type 2 diabetes management, these medications are now generating excitement for an entirely different reason: their potential role in treating arthritis. Emerging clinical evidence suggests that GLP-1 agonists may not only reduce joint pain but also slow the structural progression of osteoarthritis. But is the hype warranted, and what are the risks patients need to understand?
How Do GLP-1 Agonists Promote Weight Loss?
The cornerstone of arthritis management has always been lifestyle modification — diet, exercise, and weight loss. GLP-1 receptor agonists amplify these efforts through a dual mechanism. They target specific regions in the brain that regulate hunger and appetite while also slowing gastric emptying, which means food stays in the stomach longer and patients feel full for extended periods. Together, these effects promote a sustained calorie deficit that leads to meaningful weight loss.
A systematic review and network meta-analysis of 23 randomized controlled trials found that semaglutide 2.4 mg produced an average weight reduction of 12.5 kg (approximately 27.5 pounds) over 12 to 15 months, making it the most effective GLP-1 agonist for weight loss. This degree of weight reduction carries comprehensive health benefits, including improved cardiovascular health, lower blood pressure, enhanced insulin sensitivity, better glucose control, and positive effects on mental health, sleep, and cognitive function.
Can GLP-1 Agonists Slow Arthritis Progression?
Weight loss has long been recognized as one of the most effective non-surgical strategies for managing knee osteoarthritis. The question is whether GLP-1 agonist-induced weight loss translates into measurable improvements in joint health — and a landmark cohort study from Shanghai suggests it does.
Published in the Annals of the Rheumatic Diseases, this prospective multicenter study followed patients with knee osteoarthritis and comorbid type 2 diabetes. Compared to patients not taking GLP-1 agonists, the treatment group demonstrated significantly greater weight loss (an adjusted mean difference of 7.3 kg), improved WOMAC pain and function scores, reduced reliance on pain-relieving medications, fewer cortisone injections, and a lower rate of knee surgery (1.7% versus 5.9%). Perhaps most encouraging, MRI imaging revealed that the rate of cartilage loss in the medial femorotibial joint was significantly slower in the GLP-1 group. Long-term follow-up showed these improvements were sustained over time, and mediation analysis indicated that approximately 32% of the reduced surgical risk was attributable to weight loss itself.
The Muscle Loss Problem: Why Body Composition Matters
Despite the promising arthritis data, there is a critical concern that every patient should understand. GLP-1 agonists create a calorie deficit that resembles a physiological state of energy restriction. While the body preferentially burns fat for fuel, it also breaks down muscle tissue to meet its nutritional demands.
A comprehensive review examining the effects of GLP-1 receptor agonists on body composition found that in over half of the studies analyzed, lean body mass accounted for 20 to 50 percent of total weight lost. This is broadly consistent with diet-induced weight loss and bariatric surgery, but at the higher end of that range, the muscle loss becomes clinically significant.
In my practice, I emphasize to patients that losing 30 pounds sounds impressive — but if a disproportionate amount comes from muscle rather than fat, the net effect on body composition may actually be worse than baseline. This is especially important for patients with arthritis, tendinopathy, or other musculoskeletal conditions. Muscles are the primary stabilizers of our joints, and muscle weakness is one of the strongest predictors of worsening joint pain.
Why Muscle Preservation Is a Matter of Life and Death
The consequences of unchecked muscle loss extend far beyond joint pain. As we age, the progressive decline in skeletal muscle mass — known as sarcopenia — is one of the greatest threats to functional independence. Sarcopenia increases the risk of falls, fractures, and disability, with hip fractures carrying particularly devastating outcomes.
A systematic review of national hip fracture registries from 36 countries found that one-year mortality rates following a hip fracture in older adults range from approximately 15 to 30 percent. In practical terms, if ten older adults suffer a hip fracture, two to three of them are likely to die within one year — a mortality rate significantly higher than age-matched individuals without a hip fracture. This underscores why preserving muscle mass during weight loss is not optional but essential, particularly for older patients considering GLP-1 therapy.
What Happens When You Stop Taking GLP-1 Medications?
The second major concern with GLP-1 agonists is the tendency for rapid weight regain once the medication is discontinued. This pattern reflects a fundamental reality: most patients do not establish lasting changes to their eating and exercise habits while on the medication. When the appetite-suppressing effect disappears, old dietary patterns return.
Compounding this problem, sustained caloric restriction can downregulate metabolic rate. A patient who previously burned 2,000 calories per day may see their resting metabolic rate drop to 1,500 or even 1,200 calories per day. Returning to prior eating habits against this metabolic backdrop creates the conditions for rapid rebound weight gain.
The STEP 1 trial extension, published by Wilding et al., demonstrated this clearly. While semaglutide 2.4 mg produced a mean weight loss of 17.3% over 68 weeks, participants regained approximately two-thirds of that weight within one year of stopping the medication. Cardiometabolic improvements seen during treatment similarly reverted toward baseline values.
How to Use GLP-1 Agonists Safely for Arthritis Management
The key takeaway is that GLP-1 agonists should never be viewed as a standalone solution or a quick fix. The patients who achieve the best long-term outcomes are those who use the medication as one component of a comprehensive plan that includes dietary modification, portion control, and a structured exercise program incorporating both cardiovascular and strength training. The ultimate goal is to build sustainable habits so the medication can eventually be discontinued while maintaining a stable weight.
It is also worth noting that newer GLP-1 formulations, such as tirzepatide (Mounjaro), may have a more favorable lean mass preservation profile compared to earlier agents like semaglutide, although more research is needed to confirm this. Regardless of which medication is prescribed, concurrent resistance training and adequate protein intake are non-negotiable for protecting muscle mass.
Whether GLP-1 agonists ultimately become a standard treatment for arthritis will depend heavily on how well the muscle loss issue can be managed. However, the preliminary data is very promising, and for patients who combine the weight loss benefits with a disciplined strengthening regimen, the potential for meaningful improvements in pain, function, and disease progression is significant. If you are interested in learning more about non-surgical approaches to managing arthritis, I encourage you to schedule a consultation to discuss your options.
References
1. Xie Z, Yang S, Deng W, Li J, Chen J. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. Clinical Epidemiology. 2022;14:1463-1476. doi:10.2147/CLEP.S391819
2. Zhu H, Zhou L, Wang Q, et al. Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Annals of the Rheumatic Diseases. 2023;82(9):1218-1226. doi:10.1136/ard-2023-223845
3. Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinology and Metabolism. 2019;34(3):247-262. doi:10.3803/EnM.2019.34.3.247
4. Downey C, Kelly M, Quinlan JF. Changing trends in the mortality rate at 1-year post hip fracture — a systematic review. World Journal of Orthopedics. 2019;10(3):166-175. doi:10.5312/wjo.v10.i3.166
5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity & Metabolism. 2022;24(8):1553-1564. doi:10.1111/dom.14725
Medical Disclaimer: This content is for educational purposes only and does not substitute for the medical advice of a physician. Always consult your healthcare provider before beginning any new treatment program. The information presented reflects the opinion of Dr. Jeffrey Peng and does not represent the views of his employers or affiliated hospital systems.
Comments